Atrial fibrillation: a developmental point of view. by Mommersteeg, M, Christoffels, V, Anderson, R, Moorman, A

Immunophenotype and cytogenetic characteristics in the relationship between birth weight and childhood leukemia. by O'Neill, K, Bunch, K, Vincent, T, Spector, L, Moorman, A, Murphy, M

Cytogenetic-specific heterogeneity in the kinetics of minimal residual disease (MIRD) clearance in childhood lymphoblastic leukaemia (ALL) by Moorman, A, Richards, S, Hancock, J, Mitchell, C, Vora, A, Harrison, C, Goulden, N

Cytogenetic-specific heterogeneity in the kinetics of minimal residual disease (MRD) clearance in childhood acute lymphoblastic leukaemia (ALL) by Moorman, A, Richards, S, Hanock, J, Mitchell, C, Vora, A, Harrison, C, Goulden, N

TBX3 and its splice variant TBX3 + exon 2a are functionally similar. by Hoogaars, WM, Barnett, P, Rodriguez, M, Clout, D, Moorman, A, Goding, C, Christoffels, V

Transcription factor Tbx3 is required for the specification of the atrioventricular conduction system. by Bakker, M, Boukens, B, Mommersteeg, M, Brons, J, Wakker, V, Moorman, A, Christoffels, V

Antigen receptor gene rearrangements reflect on the heterogeneity of adult Acute Lymphoblastic Leukaemia (ALL) with implications of cell-origin of ALL subgroups - a UKALLXII study. by Rai, L, Casanova, A, Moorman, A, Richards, S, Buck, G, Goldstone, A, Fielding, A, Foroni, L

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymp... by Vora, A, Goulden, N, Mitchell, C, Hancock, J, Hough, R, Rowntree, C, Moorman, A, Wade, R

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymp... by Vora, A, Goulden, N, Mitchell, C, Hancock, J, Hough, R, Rowntree, C, Moorman, A, Wade, R

Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol. by Patrick, K, Wade, R, Goulden, N, Rowntree, C, Hough, R, Moorman, A, Mitchell, C, Vora, A

Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol by Patrick, K, Wade, R, Goulden, N, Rowntree, C, Hough, R, Moorman, A, Mitchell, C, Vora, A

Pitx2c and Nkx2-5 are required for the formation and identity of the pulmonary myocardium. by Mommersteeg, M, Brown, N, Prall, O, de Gier-de Vries, C, Harvey, R, Moorman, A, Christoffels, V

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukaemia (ALL): Analysis of cytogenetic data from 1,235 patients on the medical research council (MRC) U... by Moorman, A, Harrison, C, Richards, S, Fielding, A, Tallman, MS, Litzow, MR, Rowe, J, Goldstone, A, Dewald, G

Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council... by Krishnan, S, Wade, R, Moorman, A, Mitchell, C, Kinsey, SE, Eden, T, Parker, C, Vora, A, Richards, S, Saha, V

Two distinct pools of mesenchyme contribute to the development of the atrial septum. by Mommersteeg, M, Soufan, A, de Lange, F, van den Hoff, M, Anderson, R, Christoffels, V, Moorman, A

Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003 by Patrick, K, Wade, R, Goulden, N, Mitchell, C, Moorman, A, Rowntree, C, Jenkinson, S, Hough, R, Vora, A

Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. by Patrick, K, Wade, R, Goulden, N, Mitchell, C, Moorman, A, Rowntree, C, Jenkinson, S, Hough, R, Vora, A

Delineation of Risk Factors in Paediatric Acute Lymphoblastic Leukaemia with Favourable Cytogenetics by Moorman, A, Enshaie, A, Chilton, L, Schwab, C, Tembo, T, Richards, S, Kinsey, S, Vora, A, Mitchell, C, Harrison, C

Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. by Moorman, A, Ensor, H, Richards, S, Chilton, L, Schwab, C, Kinsey, SE, Vora, A, Mitchell, C, Harrison, C

Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplificatio... by Moorman, A, Robinson, H, Schwab, C, Richards, S, Hancock, J, Mitchell, C, Goulden, N, Vora, A, Harrison, C